Agenus to Present at the ROTH Annual Conference

Agenus to Present at the ROTH Annual Conference

LEXINGTON, Mass., March 14, 2013 (GLOBE NEWSWIRE) -- Agenus Inc.
(Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious
diseases, today announced that the company will be presenting at the 25^th
Annual ROTH Conference, which will be held at the Ritz Carlton, Laguna Nigel
in Dana Point, California.

Jonae R. Barnes, Vice President of Investor Relations and Corporate
Communications of Agenus, will present a corporate overview on Monday, March
18^th in Salon 5, Pink at 3:00 pm PT.

Between Agenus and its partners, 19 programs are in clinical development.
Agenus' QS-21 Stimulon^® adjuvant^1 is being studied in clinical trials for 17
vaccine indications. They include:

  oPhase 3: GSK's RTS,S for malaria^2
  oPhase 3: GSK's MAGE-A3 cancer immunotherapy for selected patients with
    resected melanoma^2
  oPhase 3: GSK's MAGE-A3 cancer immunotherapy for selected patients with
    resected non-small cell lung cancer^2
  oPhase 3: GSK's HZ/su for shingles^2
  oPhase 2: Janssen's ACC-001 for Alzheimer's disease

Agenus pipeline programs include:

  oPhase 2: HerpV (contains QS-21 Stimulon) for genital herpes
  oPhase 2: Prophage Series G-100 for newly diagnosed glioma
  oPhase 2: Prophage Series G-200 for recurrent glioma

Saponin Platform: QS-21 Stimulon^®Adjuvant 

Agenus' licensees include GlaxoSmithKline and Janssen Alzheimer Immunotherapy.
Agenus is generally entitled to receive milestone payments as QS-21
Stimulon-containing programs advance, as well as royalties for 10 years after
commercial launch, with some exceptions.

Heat Shock Protein Platform: Recombinant Series HerpV 

HerpV is the most advanced HSV-2 therapeutic vaccine currently in clinical
development for the treatment of genital herpes. A Phase 2 study measuring the
effect of vaccination on viral shedding in individuals infected with HSV-2 is
underway.Data results for this study are anticipated in Q4'13. Experts in
HSV-2 clinical research believe that a reduction in viral shedding could
translate into the clinical benefit of a reduction in recurrent outbreaks.

Heat Shock Protein Platform: Prophage Series G

The Prophage Series G vaccines (HSPPC-96; vitespen) are being studied in two
different settings of glioma: newly diagnosed and recurrent disease. Glioma is
the deadliest form of brain cancer with an average survival of six to 14
months.

Web Cast Information 

The live and archived webcast of the company presentation will be accessible
from the company's website at www.agenusbio.com/webcast. Please log in
approximately 5-10 minutes before each event to ensure a timely connection.
The archived replay will be available on the Agenus website for one month
following the conference.

About Agenus

Agenus Inc. is a biotechnology company working to develop treatments for
cancers and infectious diseases. The company is focused on immunotherapeutic
products based on strong platform technologies with multiple product
candidates advancing through the clinic, including several product candidates
that have advanced into late-stage clinical trials through corporate partners.
For more information, please visit www.agenusbio.com.

The Agenus logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8187

Forward-Looking Statement 

This press release contains forward-looking statements, including statements
regarding up-coming presentations and technologies, programs, and activities
of the company and its licensees. These forward-looking statements are subject
to risks and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission for the period ended
September 30, 2012. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Agenus undertakes
no obligation to update or revise the statements. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement. Agenus' business is subject to substantial risks and uncertainties,
including those identified above. When evaluating Agenus' business and
securities, investors should give careful consideration to these risks and
uncertainties.

1. QS-21 Stimulon adjuvant and the related agreements, and HerpV are assets of
Antigenics Inc., a wholly owned subsidiary of Agenus Inc.

2. QS-21 Stimulon is a component of certain GSK adjuvant systems.

Stimulon is a registered trademark of Agenus Inc. and its subsidiaries.

CONTACT: Media and Investor Contact:
         Jonae R. Barnes
         Vice President
         Investor Relations and
         Corporate Communications
         jonae.barnes@agenusbio.com
         617-818-2985

company logo
 
Press spacebar to pause and continue. Press esc to stop.